Amylyx Pharmaceuticals Inc (NASDAQ: AMLX)’s stock price has decreased by -4.17 compared to its previous closing price of 3.60. However, the company has seen a 8.49% increase in its stock price over the last five trading sessions. accesswire.com reported 2025-01-14 that NEW YORK CITY, NY / ACCESSWIRE / January 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. (“Amylyx” or “the Company”) (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/AMLX.
Is It Worth Investing in Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) Right Now?
Additionally, the 36-month beta value for AMLX is -0.54. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 1 rating it as “overweight,” 3 rating it as “hold,” and 0 rating it as “sell.”
The public float for AMLX is 43.43M and currently, short sellers hold a 4.47% ratio of that float. The average trading volume of AMLX on January 22, 2025 was 1.21M shares.
AMLX’s Market Performance
AMLX’s stock has seen a 8.49% increase for the week, with a -19.39% drop in the past month and a -11.99% fall in the past quarter. The volatility ratio for the week is 8.33%, and the volatility levels for the past 30 days are at 7.27% for Amylyx Pharmaceuticals Inc The simple moving average for the last 20 days is -7.95% for AMLX stock, with a simple moving average of 14.53% for the last 200 days.
Analysts’ Opinion of AMLX
Many brokerage firms have already submitted their reports for AMLX stocks, with Robert W. Baird repeating the rating for AMLX by listing it as a “Outperform.” The predicted price for AMLX in the upcoming period, according to Robert W. Baird is $11 based on the research report published on November 18, 2024 of the previous year 2024.
BofA Securities, on the other hand, stated in their research note that they expect to see AMLX reach a price target of $10, previously predicting the price at $4.20. The rating they have provided for AMLX stocks is “Buy” according to the report published on October 23rd, 2024.
Mizuho gave a rating of “Neutral” to AMLX, setting the target price at $4 in the report published on March 18th of the previous year.
AMLX Trading at -25.87% from the 50-Day Moving Average
After a stumble in the market that brought AMLX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -82.71% of loss for the given period.
Volatility was left at 7.27%, however, over the last 30 days, the volatility rate increased by 8.33%, as shares sank -12.44% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -40.62% lower at present.
During the last 5 trading sessions, AMLX rose by +8.49%, which changed the moving average for the period of 200-days by +31.18% in comparison to the 20-day moving average, which settled at $3.75. In addition, Amylyx Pharmaceuticals Inc saw -8.73% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AMLX starting from Klee Justin B., who sale 7,471 shares at the price of $4.04 back on Jan 06 ’25. After this action, Klee Justin B. now owns 3,176,788 shares of Amylyx Pharmaceuticals Inc, valued at $30,202 using the latest closing price.
Cohen Joshua B, the Co-Chief Executive Officer of Amylyx Pharmaceuticals Inc, sale 7,471 shares at $4.05 during a trade that took place back on Jan 06 ’25, which means that Cohen Joshua B is holding 3,213,098 shares at $30,232 based on the most recent closing price.
Stock Fundamentals for AMLX
Current profitability levels for the company are sitting at:
- -1.27 for the present operating margin
- 0.32 for the gross margin
The net margin for Amylyx Pharmaceuticals Inc stands at -1.32. The total capital return value is set at -1.27. Equity return is now at value -84.43, with -72.35 for asset returns.
Based on Amylyx Pharmaceuticals Inc (AMLX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -37.04. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -72.13.
Currently, EBITDA for the company is 39.89 million with net debt to EBITDA at 0.28. When we switch over and look at the enterprise to sales, we see a ratio of 1.15. The receivables turnover for the company is 113.51for trailing twelve months and the total asset turnover is 0.78. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.55.
Conclusion
In conclusion, Amylyx Pharmaceuticals Inc (AMLX) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
